FHIRsmith: FHIR Resources

FHIR IG analytics

Version: All | R2 | R2B | R3 | R4 | R4B | R5 | R6
Authority: All | hl7 | ihe | national
Realm: All | au | be | br | ca | ch | cl | cr | cz | de | dk | ee | eu | fi | fr | il | in | it | jp | kr | nl | no | nz | pl | pt | se | stt | tw | uk | us | uv
View: All | Resource Profiles | Datatype Profiles | Extensions | Logical Models | CodeSystems | ValueSets | ConceptMaps

ValueSets

83,706 resources

By Version

R2: 25
R2B: 0
R3: 4,057
R4: 53,170
R4B: 16,317
R5: 9,909
R6: 113

By Authority

none: 49,849
hl7: 31,823
ihe: 138
national: 1,366
who: 530

By Realm

none: 47,331
au: 99
be: 130
br: 70
ca: 276
ch: 404
cl: 220
cr: 9
cz: 157
de: 835
dk: 514
ee: 35
eu: 413
fi: 4
fr: 871
il: 148
in: 48
it: 92
jp: 71
kr: 20
nl: 902
no: 6
nz: 9
pl: 83
pt: 3
se: 10
tw: 187
us: 14,204
uv: 16,551
other: 4

Start Prev Rows 46600 - 46800 Next

Package	Version	Identity	Name/Title	Status	Date	Realm	Auth	Source(s)
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1248.354.json	Bladder Cancer for Urology Care	active	2025-03	us	hl7	icd
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1248.355.json	Chemotherapy Agents for Advanced Cancer	active	2025-03	us	hl7	rx
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1248.356.json	Cystectomy for Urology Care	active	2025-03	us	hl7	cpt
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1248.357.json	Cystectomy for Urology Care	active	2025-03	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1248.358.json	Cystectomy for Urology Care	active	2025-03	us	hl7	vsac
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1248.359.json	DEXA Bone Density for Urology Care	active	2025-03	us	hl7	loinc
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1248.360.json	Hospital Services for Urology Care	active	2025-03	us	hl7	cpt
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1248.361.json	Immunocompromised Conditions	active	2025-03	us	hl7	icd
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1248.362.json	Immunocompromised Conditions	active	2025-03	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1248.363.json	Immunocompromised Conditions	active	2025-03	us	hl7	vsac
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1248.364.json	Immunosuppressive Drugs for Urology Care	active	2025-03	us	hl7	rx
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1248.365.json	Mixed Histology Urothelial Cell Carcinoma for Urology Care	active	2025-03	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1248.366.json	Morbid Obesity	active	2025-03	us	hl7	icd
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1248.367.json	Morbid Obesity	active	2025-03	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1248.368.json	Morbid Obesity	active	2025-03	us	hl7	vsac
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1248.369.json	Unavailability of Bacillus Calmette Guerin for Urology Care	active	2025-03	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1248.370.json	Urinary Retention	active	2025-03	us	hl7	icd
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1248.371.json	Urinary Retention	active	2025-03	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1248.372.json	Urinary Retention	active	2025-03	us	hl7	vsac
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1248.374.json	Face to Face Interaction	active	2025-03	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1248.375.json	Face to Face Interaction	active	2025-03	us	hl7	vsac
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1248.376.json	HIV Viral Load Tests	active	2025-03	us	hl7	loinc
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1248.377.json	HIV Viral Load Tests	active	2025-03	us	hl7	vsac
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1248.389.json	Syphilis Tests	active	2025-04	us	hl7	loinc
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1248.4.json	Nephrectomy	active	2023-02	us	hl7	cms
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1248.8.json	Large Body Surface Area (BSA) Burns	active	2022-04	us	hl7	icd
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1250.2.json	Psychological Neuropsychological or Neurobehavioral Testing	active	2023-11	us	hl7	vsac
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1250.3.json	Psychological or Neuropsychological Testing	active	2023-11	us	hl7	cpt
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1251.10.json	Tricuspid Valve Regurgitation	active	2023-02	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1251.2.json	Valvular Heart Disease	active	2022-05	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1258.1.json	Gonorrhea Screening	active	2025-02	us	hl7	loinc
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1258.2.json	Abnormal Weight Loss	active	2024-10	us	hl7	icd
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1259.2.json	Prescribable brand and generic non insulin drugs for hyperglycemia in Type 2 Diabetes	active	2023-02	us	hl7	rx
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1259.3.json	Prescribable brand and generic insulins and analogues	active	2023-02	us	hl7	rx
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1259.4.json	eGFR Using 2021 Race Free Formulas	active	2023-02	us	hl7	loinc
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1259.5.json	Fructosamine in Serum or Plasma	active	2023-02	us	hl7	loinc
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1259.6.json	Glucose tests in venous blood, capillary blood, serum/plasma for Diabetes	active	2023-02	us	hl7	loinc
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1259.7.json	Creatinine in serum/plasma	active	2023-02	us	hl7	loinc
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1259.9.json	IgE Agonists, prescribable	active	2023-08	us	hl7	rx
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.10.json	Estrogen Receptor Testing for Orserdu	active	2023-08	us	hl7	loinc
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.100.json	MMR Proficient	active	2024-01	us	hl7	vsac
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.101.json	Systemic Cancer Directed Therapy	active	2024-02	us	hl7	rx
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.102.json	Face To Face Interaction	active	2024-02	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.104.json	Erdafitinib	active	2024-02	us	hl7	rx
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.107.json	Chemotherapy Encounter	active	2024-02	us	hl7	cpt
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.108.json	Urothelial Cancers ICD9	active	2024-02	us	hl7	icd
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.109.json	Urothelial Cancer ICD10	active	2024-02	us	hl7	icd
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.110.json	Urothelial Cancers	active	2024-02	us	hl7	vsac
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.111.json	Prior Therapies for Erdafitinib	active	2024-02	us	hl7	rx
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.112.json	Urothelial Cancer Histologies	active	2024-02	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.113.json	Malignant Tumor Behavior	active	2024-02	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.114.json	Localized Bladder Cancer Stage SNOMED	active	2024-02	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.116.json	Localized Bladder Cancer Staging	active	2024-02	us	hl7	vsac
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.117.json	Advanced Bladder Cancer Stage	active	2024-02	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.118.json	Localized Bladder Cancer T Stage	active	2024-02	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.119.json	Localized Bladder Cancer T Stage	active	2024-02	us	hl7	vsac
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.120.json	Localized Bladder Cancer N Stage	active	2024-02	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.121.json	Localized Bladder Cancer M Stage	active	2024-02	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.122.json	Advanced Bladder Cancer M Stage	active	2024-02	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.124.json	Locoregional Urothelial Cancer ICD9	active	2024-02	us	hl7	icd
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.125.json	Locoregional Urothelial Cancer ICD10	active	2024-02	us	hl7	icd
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.126.json	Locoregional Urothelial Cancer SNOMED	active	2024-02	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.127.json	Locoregional Urothelial Cancer	active	2024-02	us	hl7	vsac
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.128.json	FGFR3 Gene	active	2024-02	us	hl7	ncit
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.129.json	FGFR3 Gene Interpretation Positive SNOMED	active	2024-02	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.130.json	FGFR3 Gene Interpretation Positive LOINC	active	2024-02	us	hl7	loinc
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.131.json	FGFR3 Gene Interpretation Positive NCI	active	2024-02	us	hl7	ncit
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.133.json	FGFR3 Gene Interpretation Positive	active	2024-02	us	hl7	vsac
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.134.json	FGFR3 Gene Interpretation Negative SNOMED	active	2024-02	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.135.json	FGFR3 Gene Interpretation Negative NCI	active	2024-02	us	hl7	ncit
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.137.json	FGFR3 Gene Interpretation Negative	active	2024-02	us	hl7	vsac
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.138.json	FGFR3 Molecular Variants	active	2024-02	us	hl7	ncit
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.139.json	Tumor Behavior	active	2024-02	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.140.json	Physcological Support for Cancer	active	2024-02	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.141.json	Referral For Pain From Cancer	active	2024-04	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.142.json	Cancer Pain Education	active	2024-02	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.143.json	Telehealth Encounters	active	2024-02	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.144.json	Pain Assessment Score	active	2024-02	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.146.json	Telehealth Encounters SNOMEDCT	active	2024-03	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.147.json	Telehealth Encounters CPT	active	2024-03	us	hl7	cpt
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.148.json	Telehealth Encounters HCPCS	active	2024-03	us	hl7	cms
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.149.json	Telehealth Encounters All	active	2024-03	us	hl7	vsac
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.150.json	Chemo Admin SNOMEDCT	active	2024-03	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.151.json	Chemo Admin CPT	active	2024-03	us	hl7	cpt
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.152.json	Chemo Admin HCPCS	active	2024-03	us	hl7	cms
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.153.json	Chemotherapy Administration All	active	2024-03	us	hl7	vsac
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.154.json	Radiation Treatment CPT	active	2024-04	us	hl7	cpt
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.155.json	Radiation Treatment HCPCS	active	2024-03	us	hl7	cms
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.156.json	Radiation Treatment SNOMEDCT	active	2024-03	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.157.json	Radiation Treatment All	active	2024-03	us	hl7	vsac
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.158.json	Bipolar Diagnosis Codes	active	2024-03	us	hl7	icd
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.159.json	Telephone Visits SNOMED	active	2024-03	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.160.json	Telephone Visit CPT	active	2024-03	us	hl7	cpt
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.161.json	Telephone Visits All	active	2024-03	us	hl7	vsac
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.162.json	Adolescent depression screening assessment	active	2024-07	us	hl7	loinc
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.163.json	Adult depression screening assessment LOINC	active	2024-07	us	hl7	loinc
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.165.json	Referral for Depression Adult	active	2024-03	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.166.json	Referrals for Adolescent Depression	active	2024-03	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.167.json	Follow Ups for Adolescent Depression	active	2024-03	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.168.json	FollowUps for Adult Depression	active	2024-03	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.169.json	Depression Screen Declined for Medical Reason	active	2024-03	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.170.json	Physical Therapy Evaluations SNOMEDCT	active	2024-03	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.171.json	Physical Therapy Evaluation CPT	active	2024-03	us	hl7	cpt
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.172.json	Physical Therapies Evaluations	active	2024-03	us	hl7	vsac
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.173.json	Non Opioid Analgesics	active	2024-03	us	hl7	rx
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.174.json	Adjuvant Analgesics	active	2024-03	us	hl7	rx
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.176.json	Lung Cancer ICD9	active	2024-04	us	hl7	icd
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.177.json	Lung Cancer ICD10	active	2024-04	us	hl7	icd
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.178.json	Lung Cancer	active	2024-03	us	hl7	vsac
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.179.json	Prior Therapies for Osimertinib	active	2024-03	us	hl7	rx
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.18.json	Stage IA	active	2023-08	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.181.json	Plan of Care for Pain	active	2024-03	us	hl7	cms
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.182.json	All Antineoplastic Agents	active	2024-04	us	hl7	rx
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.183.json	Locally Advanced NSCLC Stage Group	active	2024-04	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.185.json	Localized NSCLC Stage Group SNOMED	active	2024-04	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.186.json	Radiation Treatment Management	active	2024-04	us	hl7	cpt
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.187.json	Plan of Care	active	2024-04	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.188.json	Documentation of Plan of Care	active	2024-07	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.189.json	Pain Present	active	2024-04	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.19.json	Stage IB	active	2023-08	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.190.json	Localized NSCLC Stage Group NCIM	active	2024-04	us	hl7	ncit
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.192.json	Localized NSCLC Stage Group	active	2024-04	us	hl7	vsac
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.193.json	Advanced NSCLC Stage Group	active	2024-04	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.194.json	NSCLC M Stage (metastatic)	active	2024-04	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.195.json	NSCLC T Stage	active	2024-04	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.196.json	NSCLC N Stage	active	2024-04	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.197.json	SCLC and rarer lung cancer histology	active	2024-04	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.198.json	EGFR Gene	active	2024-04	us	hl7	ncit
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.199.json	EGFR Gene Interpretation Positive SNOMED	active	2024-04	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.20.json	Stage IIA	active	2023-08	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.200.json	EGFR Gene Interpretation Positive LOINC	active	2024-04	us	hl7	loinc
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.201.json	EGFR Gene Interpretation Positive	active	2024-04	us	hl7	vsac
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.202.json	EGFR Osimertinib Molecular Variants	active	2024-04	us	hl7	loinc
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.203.json	EGFR Generic Molecular Variant NCIM	active	2024-04	us	hl7	ncit
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.204.json	EGFR Generic Molecular Variant SNOMED	active	2024-04	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.205.json	EGFR Generic Molecular Variant LOINC	active	2024-04	us	hl7	loinc
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.206.json	EGFR Molecular Variants Osimertinib PM	active	2024-04	us	hl7	vsac
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.207.json	Osimertinib	active	2024-04	us	hl7	rx
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.208.json	Pemetrexed	active	2024-04	us	hl7	rx
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.209.json	Radiation Treatment Management SNOMEDCT	active	2024-04	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.21.json	Stage IIB	active	2023-08	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.210.json	Radiation Treatment Management Codes	active	2024-04	us	hl7	vsac
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.211.json	Radiation Treatment Delivery CPT	active	2024-04	us	hl7	cpt
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.212.json	77427 Management Code	active	2024-04	us	hl7	cpt
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.213.json	Radiation Treatment Delivery HCPCS	active	2024-04	us	hl7	cms
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.214.json	Radiation Treatment Delivery NCIM	active	2024-04	us	hl7	ncit
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.215.json	Radiation Treatment Delivery SNOMED	active	2024-04	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.216.json	Radiation Treatment Delivery	active	2024-04	us	hl7	vsac
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.217.json	MET Gene Test	active	2024-05	us	hl7	loinc
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.219.json	Tepotinib	active	2024-05	us	hl7	rx
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.22.json	Stage IIIA	active	2023-08	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.220.json	MET Positive gene interpretation	active	2024-05	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.227.json	MET Exon 14 skipping molecular variant	active	2024-05	us	hl7	ncit
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.23.json	Stage IIIB	active	2023-08	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.233.json	test43	active	2024-07	us	hl7	icd
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.234.json	ROS1 Molecular Variants Repotrectinib PM	active	2024-05	us	hl7	loinc
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.235.json	ROS1 Repotrectinib Molecular Variants	active	2024-05	us	hl7	ncit
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.236.json	ROS1 Negative (geneinterpretation) SNOMEDCT	active	2024-05	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.237.json	ROS1 Negative (geneinterpretation) NCI	active	2024-05	us	hl7	ncit
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.238.json	ROS1 Negative (geneinterpretation) SNOMEDCT,NCI	active	2024-05	us	hl7	vsac
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.239.json	ROS1 Positive (geneinterpretation)	active	2024-05	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.24.json	Stage IIIC	active	2023-08	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.240.json	ROS1 results (HGNC)	active	2024-05	us	hl7	ncit
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.241.json	ROS1 Gene Rearrangement	active	2024-05	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.246.json	RET Negative (geneinterpretaion) NCI	active	2024-06	us	hl7	ncit
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.247.json	RET Negative (geneinterpretaion) SNOMEDCT,NCI	active	2024-06	us	hl7	vsac
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.248.json	RET Fusion Molecular Variants	active	2024-06	us	hl7	ncit
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.25.json	ESR1 Gene Test	active	2023-08	us	hl7	ncit
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.250.json	Repotrectinib Value set	active	2024-06	us	hl7	rx
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.251.json	Amivantamab	active	2024-06	us	hl7	rx
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.252.json	Alectinib Drug	active	2024-06	us	hl7	rx
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.253.json	Gemcitabine Drug Value set	active	2024-06	us	hl7	rx
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.254.json	vinorelbine Drug	active	2024-06	us	hl7	rx
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.255.json	NSCLC_Tumor_resection SNOMEDCT	active	2024-06	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.256.json	NSCLC_Tumor_resection CPT	active	2024-06	us	hl7	cpt
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.257.json	NSCLC_Tumor_resection SNOMEDCT CPT	active	2024-06	us	hl7	vsac
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.258.json	ALK results (HGNC)	active	2024-07	us	hl7	loinc
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.259.json	ALK Positive (geneinterpretation) SNOMED	active	2024-06	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.26.json	ESR1 Genetic Mutation	active	2023-08	us	hl7	ncit
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.260.json	ALK Positive (geneinterpretation) NCI	active	2024-06	us	hl7	ncit
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.261.json	ALK Positive (geneinterpretation) SNOMEDCT NCI	active	2024-06	us	hl7	vsac
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.262.json	ALK Negative (geneinterpretation) SNOMEDCT	active	2024-06	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.263.json	ALK Negative (geneinterpretation) NCI	active	2024-06	us	hl7	ncit
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.264.json	ALK Negative (geneinterpretation) SNOMEDCT NCI	active	2024-06	us	hl7	vsac
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.265.json	Locoregional Sites	active	2024-06	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.266.json	NSCLC N2 Stage	active	2024-06	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.267.json	NSCLC N1 Stage	active	2024-06	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.268.json	NSCLC N0 Stage	active	2024-06	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.269.json	NSCLC T3_T4 Stage	active	2024-06	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.27.json	Genetic Test Finding	active	2023-09	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.270.json	NSCLC T2 Stage	active	2024-06	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.271.json	NSCLC T1 Stage	active	2024-06	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.272.json	Locally_Advanced_Metastatic_NSCLC Stage Group	active	2024-06	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.273.json	Localized_Inclusion_NSCLC Stage Group	active	2024-06	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.274.json	Localized_Exclusion_NSCLC Stage Group	active	2024-06	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.275.json	tarlatamab dlle	active	2024-06	us	hl7	rx
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.276.json	Extensive SCLC Stage Group SNOMEDCT	active	2024-06	us	hl7	sct
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.277.json	Extensive SCLC Stage Group NCIM	active	2024-06	us	hl7	ncit
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.278.json	Extensive SCLC Stage Group	active	2024-06	us	hl7	vsac
us.nlm.vsac	R4	ValueSet-2.16.840.1.113762.1.4.1260.279.json	Localized SCLC Stage Group	active	2024-06	us	hl7	sct